Citicoline (Encetron-Solopharm) solution 100 mg/ml 10 ml – [10 vials]

Citicoline, being a precursor of the key ultrastructural components of the cell membrane (mainly phospholipids), has a broad spectrum of action: it helps restore damaged cell membranes, inhibits the action of phospholipases, prevents the excess formation of free radicals, and also prevents cell death by acting on apoptosis mechanisms. In the acute period of stroke citicoline reduces the volume of brain tissue damage, improves cholinergic transmission. In craniocerebral trauma reduces the duration of post-traumatic coma and severity of neurological symptoms, also contributes to reducing the duration of the recovery period. In chronic cerebral hypoxia citicoline is effective in treating cognitive disorders such as memory impairment, lack of initiative, difficulty in performing daily activities and self-care.  It increases attention and consciousness, and reduces the manifestation of amnesia. Effective in treating sensory and motor neurological disorders of degenerative and vascular etiology.

– Acute phase of ischemic stroke (as part of complex therapy).

– The recovery period of ischemic and hemorrhagic strokes.

– Craniocerebral trauma, acute (as part of complex therapy) and recovery period.

– Cognitive and behavioral disorders in degenerative and vascular diseases of the brain.

Contraindications .

– Hypersensitivity to any of the components of the drug.

– Severe vagotonia (predominance of the tone of the parasympathetic autonomic nervous system).

– Children under 18 years of age (due to insufficient clinical data).

Administration during pregnancy and lactation

Sufficient data on the use of citicoline in pregnant women are not available. Although no adverse effects were found in animal studies, during pregnancy the drug is prescribed only in cases when the expected benefits to the mother outweigh the potential risk to the fetus.

When prescribing the drug during lactation, women should stop breastfeeding, since there is no data on excretion of citicoline and its metabolites with breast milk. The risk to the child cannot be excluded.

• The solution for oral administration is used orally.
• The drug may be diluted in a small amount of water (100-120 ml or 1/2 cup) before use. It is taken with a meal or between meals.
• Recommended dosage regimen
• Acute period of ischemic stroke or traumatic brain injury (TBI): 1000 mg (10 ml) every 12 hours. Duration of treatment is at least 6 weeks.
• Recovery period of ischemic and hemorrhagic strokes, the recovery period of CHT, cognitive and behavioral disorders in degenerative and vascular brain diseases: 500-2000 mg (5-20 ml) per day. Dosage and duration of treatment – depending on the severity of the symptoms.
• Elderly patients
• When prescribing citicoline in elderly patients no dose adjustment is required.